Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence and Food Effect Study of Macitentan/Tadalafil FDC
NCT04235270Phase 1Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Jan 2020
- Primary completion
- Jul 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of macitentan and tadalafil in pulmonary arterial hypertension (PAH) (2 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Maximum Observed Plasma Analyte Concentration of Tadalafil, Area Under the Concentration-time Curve from Time Zero to Last Quantifiable Concentration of Tadalafil and 4 more. Started Jan 2020; status: completed.
02
Drugs
macitentantadalafil
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on NCT04235270.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04235270.